Volume 11, Number 10—October 2005
Research
Community-associated Methicillin-resistant Staphylococcus aureus, Minnesota, 2000–2003
Table 3
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) invasive disease patient and skin and soft tissue infection (SSTI) patient isolate characteristics*
Antimicrobial agent | Invasive disease isolates (n = 57), no. (% susceptible) | SSTI isolates (n = 517), no. (% susceptible) | OR (95% CI) | p value† | p value‡ |
---|---|---|---|---|---|
Oxacillin (methicillin) | 0 | 0 | NA | ||
Ciprofloxacin | 37 (65) | 433 (84) | 3.34 (1.67–6.69) | 0.002 | 0.23 |
Clindamycin | 44 (77) | 475 (92) | 2.79 (1.54–5.04) | 0.001 | 0.20 |
Erythromycin | 21 (37) | 201 (39) | 1.09 (0.62–1.92) | ||
Gentamicin | 56 (98) | 509 (98) | 1.14 (0.14–9.25) | ||
Linezolid | 57 (100) | 517 (100) | NA | ||
Mupirocin | 56 (98) | 508 (98) | 1.14 (0.14–9.23) | ||
Rifampin | 56 (98) | 515 (99) | 4.60 (0.41–51.5) | ||
Tetracyline | 52 (91) | 469 (91) | 0.94 (0.36–2.46) | ||
Trimethoprim-sulfamethoxazole | 56 (98) | 514 (99) | 3.06 (0.31–2.99) | ||
Vancomycin | 57 (100) | 517 (100) | NA |
*OR, odds ratio; CI, confidence interval; NA, not applicable.
†Refers to the probablility that the percentage susceptible for invasive CA-MRSA isolates differed from SSTI CA-MRSA isolates after controlling for sex and age.
‡Refers to the probability that the percentage susceptible for invasive CA-MRSA isolates differed from SSTI CA-MRSA isolates after controlling for sex and pulsed-field type associated with healthcare-associated MRSA or CA-MRSA.